chcuk@syneoshealth.com
  • Home
  • Contact
CHCUK
  • NIS
    • NIS Definitions
    • Study Classification
    • NIS Training Solutions
    • NIS Country-Specific Reports
    • NIS Regulatory Database
    • NIS Regulatory Consulting
    • NIS Resources & Useful Links
    • RWR Glossary
  • PCTs
    • PCT Definitions
    • PCT Regulatory Consulting
    • PCT Useful Links
    • RWR Glossary
  • GCP
    • GCP Definitions
    • GCP Useful Links
    • RWR Glossary
  • News
  • About
  • Contact
Select Page

EU: Looking Towards the Future – Brainstorming on Funding Mechanisms for PAS

12 Dec, 2015 | CHCUK News & Articles, Consultation, GCP, News, NIS, Pragmatic Trials, Real Word Evidence

ConsultationIntroduction

(Highlights from the ENCePP Plenary Meeting, 24 November 2015)
Xavier Kurz set the scene by presenting a brief introduction highlighting ENCePP’s potential role and contribution so far to the regulatory need for continuous monitoring and investigation of benefit/risk profiles of medicines.

  • Scenario 1: Proposal for a Central Mechanism for Industry-Funded Studies (Tom MacDonald)
  • Scenario 2: Proposal on Medication Safety in Pregnancy (Helen Dolk)
  • Scenario 3: Different Governance Models for Collaborative Vaccine Studies Based on the Work of the ADVANCE Project (Xavier Kurz)

Discussion and Way Forward

In conclusion, Miriam Sturkenboom and Alison Bourke summarised the discussions as follows:

  • The ENCePP Code of Conduct and its provisions regarding independence and industry stakeholder involvement remain current and helpful.
  • It was agreed that funding should come from industry, but administered by an independent organisation; different options need to be explored further.
  • In addition, in order to secure independent/public funding in the future, ENCePP should make use of its collective influence and make the case at European level. Setting up a virtual group is proposed.Peter Arlett confirmed that the outcome of the discussions will be furthered at Steering Group level at its meeting on 16th December 2015.

 
[Read more…]

Categories

  • 21 Century Cures Act
  • 3D Printers
  • AI
  • Biological Products
  • Biosamples
  • Biosimilars
  • Brexit
  • CHCUK News & Articles
  • CHCUK NIS Database
  • Consultation
  • Cures Act
  • Cybersecurity
  • Data Integrity
  • Data Privacy
  • Digital Health Technology
  • EAP
  • eConsent
  • EFPIA
  • EHR
  • eletronic Signatures
  • EMA
  • EU Clinical Trials Regulation
  • FDA 1572
  • FDA Guidance
  • FDAMA114
  • GCP
  • GCP Inspections
  • GDPR
  • Genetic Research
  • GVP
  • HIPAA
  • HTA
  • Human Tissue Research
  • Immunological Products
  • Informed Consent
  • Market Access
  • Medical Apps
  • Medical Devices
  • News
  • NIS
  • NIS Considerations Report
  • Orphan Drugs
  • PASS
  • Patient Centricity
  • Pragmatic Trials
  • Professional Standards
  • Promotion and Advertising
  • PROs
  • Publication Guidelines
  • Rare Diseases
  • Real Word Evidence
  • Real World Evidence
  • Real World Research Design
  • Registry
  • Regulatory Grade RWE
  • Regulatory Intelligence
  • Regulatory Science
  • Reimbursement
  • RWD
  • Safety Management
  • Sunshine Regulations
  • Transparency
  • Uncategorized
  • Virtual Clinical Research
  • Webinar
  • White Paper

News

July 2022
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
« Feb    

Legal Information:

  • Terms & Conditions
  • Disclaimer
  • Privacy Notice

• CHCUK NIS Regulatory Database
• Contact CHCUK

  • Facebook
  • Twitter
Copyright © 2018 CHCUK. All Rights Reserved.

design by Poppy Design